Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.
Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera
Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450million at a facility in North Carolina t
One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been
Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of the population, with over 90% included in the type 2 category.
Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl